FDA device listing
ACCURUN 325 HBV DNA Positive Control Series 200,ACCURUN 325 HBV DNA Positive Control Series 370,ACCURUN 325 HBV DNA…
FDA device listing 1170268785 · LGC Clinical Diagnostics, Inc.
Key facts
| Proprietary names | ACCURUN 325 HBV DNA Positive Control Series 200,ACCURUN 325 HBV DNA Positive Control Series 370,ACCURUN 325 HBV DNA Positive Control Series 700,ACCURUN 345 HIV-1 RNA, HCV RNA, HBV DNA Positive Quality Control Series 150 |
|---|---|
| Owner/operator | LGC Clinical Diagnostics, Inc. |
| Owner/operator number | 9041170 |
| Premarket submissions | BK040064 |
| Product codes | JJX |
| Device names | JJX - Single (Specified) Analyte Controls (Assayed And Unassayed) |
| Device class | Class I |
| Classification regulations (21 CFR) | 862.1660 |
| Review panels | Clinical Chemistry |
| Registered establishments | LGC Clinical Diagnostics, Inc. |
| Establishment registrations | 3007088335 |
| FEI numbers | 1220394 |
| Establishment operations | Manufacturer |
| Registration valid through | 2026 |
At a glance
- 1–9 Registered establishments listing this device
- 1–9 UDI devices (GUDID) under the same submission
- 1–9 Device listings citing the same submission
- Yes Premarket submission listed
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA device listings
Establishments that make or process devices for the U.S. market must list each device with the FDA. A listing records the device's proprietary names, product codes and premarket submission, and every registered establishment that handles it.
Source: U.S. Food and Drug Administration (FDA), Establishment Registration and Device Listing database